SPRCF News and Press, SciSparc Ltd Ord

SciSparc Provides Updates Upon Conclusion of 2021 PR Newswire TEL AVIV, Israel , Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the cent...

SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today PR Newswire TEL AVIV, Israel , Dec. 22, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to ...

SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market PR Newswire TEL AVIV, Israel , Dec. 20, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCF) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat di...

SciSparc Announces the Publication of a Manuscript Describing the Tourette Syndrome Study Conducted at Yale University The manuscript titled "A Pilot Study of a Therapeutic Combination of Δ9-tetrahydracannabinol and Palmitoylethanolamide for Adults with Tourette Syndrome,...

The Biotech Industry Veteran Will Assist the Company W ith Developing Additional Market Segments f or Save Foods’ Technology TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Save Foods (Nasdaq: SVFD) (“Save Foods” or the ȁ...

SciSparc Awarded Three Patents For Its Novel Compounds and Methods Applications Approved in Australia and Japan PR Newswire TEL AVIV, Israel , Sept. 7, 2021 /PRNewswire/ -- SciSparc Ltd. (OTC Pink: SPRCF), a specialty, clinical-stage pharmaceutical company fo...